In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

Marguerite L. Monogue, Jennifer Tabor-Rennie, Kamilia Abdelraouf, David P. Nicolau

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.

Original languageEnglish (US)
Article numbere00233-19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number7
DOIs
StatePublished - Jan 1 2019

Fingerprint

meropenem
Thigh
Pseudomonas aeruginosa
Infection
cefepime

Keywords

  • Human simulated
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model. / Monogue, Marguerite L.; Tabor-Rennie, Jennifer; Abdelraouf, Kamilia; Nicolau, David P.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 7, e00233-19, 01.01.2019.

Research output: Contribution to journalArticle

@article{ba6313da29dd49d392bb27c0d45ae77c,
title = "In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model",
abstract = "We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.",
keywords = "Human simulated, Pharmacodynamics, Pharmacokinetics",
author = "Monogue, {Marguerite L.} and Jennifer Tabor-Rennie and Kamilia Abdelraouf and Nicolau, {David P.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1128/AAC.00233-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "7",

}

TY - JOUR

T1 - In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

AU - Monogue, Marguerite L.

AU - Tabor-Rennie, Jennifer

AU - Abdelraouf, Kamilia

AU - Nicolau, David P.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.

AB - We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.

KW - Human simulated

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85068136678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068136678&partnerID=8YFLogxK

U2 - 10.1128/AAC.00233-19

DO - 10.1128/AAC.00233-19

M3 - Article

C2 - 31235557

AN - SCOPUS:85068136678

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 7

M1 - e00233-19

ER -